Qu Biologics, Vancouver, British Columbia-based biopharmaceutical company, has announced that William Sandborn, MD, and Richard Fedorak, MD, FRCPC, FRCP, FRSC, have joined its irritable bowel disease advisory team.
The IBD advisory team has been created to provide insight during the clinical trials of Qu Biologics' QBECO Site Specific Immunomodulator for Chrohn's disease.
Dr. Sandborn is currently the director of the IBD Center and chief of gastroenterology for the University of California San Diego Health System. He is also a professor of medicine at UC San Diego.
Dr. Fedorak is president of the Canadian Digestive Health Foundation and chairman of the research committee for the World Gastroenterology Organization. He also serves as associate vice president of research and a professor of medicine in the gastroenterology division of the University of Alberta.
More Articles on Gastroenterology:
Dr. Leslie Schoppe Joins Brownwood Regional Medical Center
AGA Appoints Dr. Anil Rustgi President
3 Benefits of Outsourcing Colonoscopy Prep
The IBD advisory team has been created to provide insight during the clinical trials of Qu Biologics' QBECO Site Specific Immunomodulator for Chrohn's disease.
Dr. Sandborn is currently the director of the IBD Center and chief of gastroenterology for the University of California San Diego Health System. He is also a professor of medicine at UC San Diego.
Dr. Fedorak is president of the Canadian Digestive Health Foundation and chairman of the research committee for the World Gastroenterology Organization. He also serves as associate vice president of research and a professor of medicine in the gastroenterology division of the University of Alberta.
More Articles on Gastroenterology:
Dr. Leslie Schoppe Joins Brownwood Regional Medical Center
AGA Appoints Dr. Anil Rustgi President
3 Benefits of Outsourcing Colonoscopy Prep